Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004
October 19, 2015 1:22 PM EDT
FBR Capital reiterated an Outperform rating on Genocea Biosciences (NASDAQ: GNCA), and cut the price target to $17.00 (from $20.00), following top-line Phase II data for GEN-004. Although the data showed consistent reductions in the rate and density of colonization compared to placebo, neither endpoint reached statistical... More
October 19, 2015 10:03 AM EDT
Needham & Company analyst Alan Carr lowered his price target on Genocea Biosciences (NASDAQ: GNCA) to $15.00 (from $22.00) announced results from its GEN-004 Phase 2 Pneumococcal Pneumonia challenge trial this morning. The firm maintained a Buy rating.
Carr commented, "Although a trend towards improvement over placebo was... More
October 19, 2015 7:02 AM EDT
Genocea Biosciences (NASDAQ: GNCA) announced that top-line results from a Phase 2a clinical trial for GEN-004, its universal vaccine candidate against pneumococcus, showed consistent reductions versus placebo in the pre-specified endpoints of the rate and density of colonization, but that neither of the endpoints achieved statistical significance. GEN-004 was safe and well tolerated by subjects.
We are currently working with our advisors to better understand these results and to determine a next step for this program. While we did not hit statistical significance in this study, the consistent apparent effect gives us... More
